RT Journal Article
SR Electronic
T1 Molecular mechanisms in multiple myeloma drug resistance
JF Journal of Clinical Pathology
JO J Clin Pathol
FD BMJ Publishing Group Ltd and Association of Clinical Pathologists
SP 97
OP 101
DO 10.1136/jclinpath-2015-203414
VO 69
IS 2
A1 Nicholas Nikesitch
A1 Silvia C W Ling
YR 2016
UL http://jcp.bmj.com/content/69/2/97.abstract
AB Multiple myeloma (MM) is predominantly an incurable malignancy despite high-dose chemotherapy, autologous stem cell transplant and novel agents. MM is a genetically heterogeneous disease and the complexity increases as the disease progresses to a more aggressive stage. MM arises from a plasma cell, which produces and secretes non-functioning immunoglobulins. Most MM cells are sensitive to proteasome inhibitors (PIs), which have become the main drug in the treatment of newly diagnosed and relapsed MM. However, not all MM is sensitive to PIs. This review summarises the literature regarding molecular biology of MM with a focus on the unfolded protein response and explores how this could affect drug sensitivity and progression of disease.